These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27060927)

  • 41. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
    PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
    Saied EM; El-Etreby NM
    Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Reversal of multi-drug resistance in ovarian cancer cell by RNA interference].
    Lou JY; Peng ZL; Zheng Y; Wang H; He B; Wang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):413-6. PubMed ID: 16831368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
    Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
    BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
    Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas.
    Schöndorf T; Scharl A; Kurbacher CM; Bien O; Becker M; Neumann R; Kolhagen H; Rustemeyer J; Mallmann P; Göhring UJ
    Cancer Lett; 1999 Nov; 146(2):195-9. PubMed ID: 10656626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
    Huang LP; Yu YH; Sheng C; Wang SH
    Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs.
    Jin W; Liu Y; Xu SG; Yin WJ; Li JJ; Yang JM; Shao ZM
    Breast Cancer Res Treat; 2010 Nov; 124(1):39-48. PubMed ID: 20037778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
    Trock BJ; Leonessa F; Clarke R
    J Natl Cancer Inst; 1997 Jul; 89(13):917-31. PubMed ID: 9214671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
    Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
    Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
    Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
    Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
    Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MicroRNA 130b enhances drug resistance in human ovarian cancer cells.
    Zong C; Wang J; Shi TM
    Tumour Biol; 2014 Dec; 35(12):12151-6. PubMed ID: 25155039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M; Ouyang Q; Goldberg MS; Amiji MM
    Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
    Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
    Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.